BioSpace News Archive

Celcuity Inc. today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021.

Titan Medical Inc. today announced the appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs.

CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced several key leadership appointments in newly created positions, including Louie Naumovski, M.D., Ph.D., as Chief Medical Officer, Amit Agarwal M.D., Ph.D., as Senior Vice President, Clinical Development, and Steve DeMattos as Senior Vice President, Clinical Operations.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced a $100 million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis, including the Phase 3 RESPONSE clinical trial.

T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing.

Lumos Pharma, Inc. has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company’s planned succession.

A team of physicians at Allegheny Health Network (AHN) has received FDA approval to begin the second phase of a groundbreaking clinical trial exploring the efficacy of deep brain stimulation (DBS) in the management of morbid obesity.

Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.

Acurx Pharmaceuticals, Inc announced today that Health Holland has awarded a grant of approximately $500,000 USD to Leiden University Medical Center (LUMC) and, through a three-party Consortium Agreement, Acurx Pharmaceuticals.